Personalis (NASDAQ:PSNL) Now Covered by Craig Hallum

Craig Hallum initiated coverage on shares of Personalis (NASDAQ:PSNL) in a research report released on Monday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $8.00 price objective on the stock.

Several other equities research analysts have also recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Personalis in a research report on Friday, February 28th. Needham & Company LLC dropped their price target on shares of Personalis from $7.25 to $7.00 and set a “buy” rating on the stock in a research report on Friday, February 28th. Finally, Lake Street Capital lifted their price target on Personalis from $7.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $7.80.

Personalis Stock Up 4.7 %

Shares of NASDAQ PSNL opened at $3.80 on Monday. The firm’s 50-day simple moving average is $4.92 and its 200 day simple moving average is $4.90. Personalis has a fifty-two week low of $1.14 and a fifty-two week high of $7.20. The stock has a market cap of $335.40 million, a P/E ratio of -2.26 and a beta of 1.73.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.09. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. The firm had revenue of $16.80 million for the quarter, compared to analysts’ expectations of $15.48 million. On average, sell-side analysts anticipate that Personalis will post -1.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Personalis

Institutional investors have recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. purchased a new position in Personalis in the 4th quarter worth about $28,000. JPMorgan Chase & Co. grew its stake in Personalis by 2,827.0% during the 4th quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company’s stock valued at $34,000 after acquiring an additional 5,654 shares in the last quarter. Olympiad Research LP purchased a new position in Personalis during the 4th quarter valued at about $59,000. Alpine Global Management LLC purchased a new position in Personalis during the 4th quarter valued at about $60,000. Finally, SG Americas Securities LLC purchased a new position in Personalis during the 4th quarter valued at about $63,000. Hedge funds and other institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.